Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

Phase 4

Completed

• Conditions: Colon Polyp; Colon Lesion; Colon Adenoma
• Interventions: Drug: PEG3350; Drug: Macrogol 4000

• Registration Number: NCT03742232
• Lead Sponsor: Istituto Clinico Humanitas

Brief Summary

This study is a multicentre randomized parallel group phase IV study comparing the bowel cleansing efficacy, safety and tolerability of PLENVU® (a 1 litre PEG Bowel Cleansing Solution) versus SELG-ESSE® (a 4 litre PEG Bowel Cleansing Solution) using a 2-Day Split Dosing Regimen.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-10-31
• Study First Submitted: 2018-11-13
• Study First Submitted QC: 2018-11-14
• Study First Posted: 2018-11-15
• Primary Completion: 2020-03-31
• Study Completion: 2020-03-31
• Status Verified: 2020-08
• Last Update Submitted: 2020-08-26
• Last Update Posted: 2020-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 399

Inclusion Criteria

1. Patients must provide written informed consent.

2. Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.

3. Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period:

   • Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom;
   • Intrauterine device in combination with a condom; Double barrier method (condom*, and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/ cream/suppository); *A female condom and a male condom should not be used together as friction between the two can result in either product failing.

   If any female patient has a positive pregnancy test at Visit 2, they will be excluded from further participation in the study for the efficacy evaluation, i.e. they will not undergo the colonoscopy procedure. The Investigator will be required to arrange a colonoscopy procedure outside of the study.

   Note: The above birth control methods do not apply to females who are postmenopausal or surgically sterile i.e. 12 months of natural (spontaneous) amenorrhea or 6 weeks' post-surgical bilateral oophorectomy with or without hysterectomy or hysterectomy, or whose sole sexual partner has had a vasectomy and has received medical assessment of the surgical success.

4. Willing, able and competent to complete the entire study and to comply with instructions.

Exclusion Criteria

1. Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
2. Patients with ongoing severe acute Inflammatory Bowel Disease (IBD).
3. Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and defunctioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
4. Regular use of laxatives or colon motility altering drugs (i.e. more than 2-3 times per week) in the last 28 days prior to the Screening Visit and/or laxative use within 72 hours prior to administration of the preparation.
5. Patients with active intestinal bleeding episodes
6. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
7. Known phenylketonuria.
8. Known hypersensitivity to polyethylene glycols, ascorbic acid and sulfates (not including sulfa-based products) or any other component of the investigational product or comparator.
9. Past history within the last 12 months or evidence of any on-going clinically relevant electrocardiogram (ECG) abnormalities (e.g. arrhythmias).
10. History of uncontrolled hypertension with systolic blood pressure >170 mmHg and diastolic blood pressure >100 mmHg.
11. Patients with cardiac insufficiency NYHA grades III or IV.
12. Patients with severe renal insufficiency.
13. Patients with known liver disease of grades B and C according to the Child Pugh classification.
14. Patients suffering from dehydration at screening as evaluated by the Investigator from physical examination.
15. Patients with pre-existing clinically significant electrolyte abnormalities, or dehydration.
16. Patients with impaired consciousness that might predispose them to pulmonary aspiration.
17. Patients undergoing colonoscopy for foreign body removal and/or decompression.
18. Patients who are pregnant or lactating, or intending to become pregnant during the study.
19. Clinically relevant findings on physical examination based on the Investigator's judgment.
20. History of drug or alcohol abuse within the 12 months prior to dosing.
21. Concurrent participation in an investigational drug or device study or participation within three months of study entry.
22. Patients who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures, e.g. cognitively impaired, debilitated or fragile patients.
23. Patients who are ordered to live in an institution on court or authority order.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
PLENVU	PEG3350	PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
SELG-ESSE	Macrogol 4000	SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.

Primary Outcome Measures

Name	Time	Method
Bowel cleansing efficacy	1 Day of colonoscopy	To evaluate the overall bowel cleansing efficacy of 2-day split-dosing with PLENVU compared to a 2-day split-dosing regimen with SELG-ESSE®, graded according to the Boston Bowel Preparation Scale (BBPS) in patients undergoing screening, surveillance or diagnostic colonoscopy.

Secondary Outcome Measures

Name	Time	Method
Adenoma Detection Rate	1 Day of colonoscopy	To assess the overall Adenoma Detection Rate with PLENVU compared to SELG-ESSE;
Adverse events	4 days after colonscopy	To assess the incidence of adverse events in PLENVU group comparing SELG-ESSE arm
Polip Detection Rate	1 Day of colonoscopy	To assess the overall Polip Detection Rate with PLENVU compared to SELG-ESSE

Trial Locations

Locations (5)

ISMETT; 🇮🇹 Palermo, Italy

Fondazione Poliambulanza; 🇮🇹 Brescia, Italia, Italy

Humanitas Research Hospital; 🇮🇹 Rozzano, Italy

Centro di Riferimento Oncologico; 🇮🇹 Aviano, Italia, Italy

Nuovo Regina Margherita Hospital; 🇮🇹 Roma, Italia, Italy